Report cover image

Global Antiviral Drugs for Influenza Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 197 Pages
SKU # APRC20359982

Description

Summary

According to APO Research, the global Antiviral Drugs for Influenza market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Antiviral Drugs for Influenza is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Antiviral Drugs for Influenza is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Antiviral Drugs for Influenza market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Antiviral Drugs for Influenza is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Antiviral Drugs for Influenza market include AdvaCare Pharma, Avexima, BioCryst Pharmaceuticals, Daiichi Sankyo, Morningside Pharmaceuticals, Shionogi, Wockhardt, GlaxoSmithKline and Roche, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Antiviral Drugs for Influenza, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Antiviral Drugs for Influenza, also provides the sales of main regions and countries. Of the upcoming market potential for Antiviral Drugs for Influenza, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antiviral Drugs for Influenza sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Antiviral Drugs for Influenza market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Antiviral Drugs for Influenza sales, projected growth trends, production technology, application and end-user industry.

Antiviral Drugs for Influenza Segment by Company

AdvaCare Pharma
Avexima
BioCryst Pharmaceuticals
Daiichi Sankyo
Morningside Pharmaceuticals
Shionogi
Wockhardt
GlaxoSmithKline
Roche
Teva Pharmaceuticals
Antiviral Drugs for Influenza Segment by Type

Neuraminidase Inhibitors
Polymerase Inhibitors
Antiviral Drugs for Influenza Segment by Application

Over-the-counter (OTC)
Prescription (Rx)
Antiviral Drugs for Influenza Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Antiviral Drugs for Influenza status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Antiviral Drugs for Influenza market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Antiviral Drugs for Influenza significant trends, drivers, influence factors in global and regions.
6. To analyze Antiviral Drugs for Influenza competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiviral Drugs for Influenza market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antiviral Drugs for Influenza and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiviral Drugs for Influenza.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antiviral Drugs for Influenza market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antiviral Drugs for Influenza industry.
Chapter 3: Detailed analysis of Antiviral Drugs for Influenza manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Antiviral Drugs for Influenza in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Antiviral Drugs for Influenza in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Antiviral Drugs for Influenza Sales Value (2020-2031)
1.2.2 Global Antiviral Drugs for Influenza Sales Volume (2020-2031)
1.2.3 Global Antiviral Drugs for Influenza Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Antiviral Drugs for Influenza Market Dynamics
2.1 Antiviral Drugs for Influenza Industry Trends
2.2 Antiviral Drugs for Influenza Industry Drivers
2.3 Antiviral Drugs for Influenza Industry Opportunities and Challenges
2.4 Antiviral Drugs for Influenza Industry Restraints
3 Antiviral Drugs for Influenza Market by Company
3.1 Global Antiviral Drugs for Influenza Company Revenue Ranking in 2024
3.2 Global Antiviral Drugs for Influenza Revenue by Company (2020-2025)
3.3 Global Antiviral Drugs for Influenza Sales Volume by Company (2020-2025)
3.4 Global Antiviral Drugs for Influenza Average Price by Company (2020-2025)
3.5 Global Antiviral Drugs for Influenza Company Ranking (2023-2025)
3.6 Global Antiviral Drugs for Influenza Company Manufacturing Base and Headquarters
3.7 Global Antiviral Drugs for Influenza Company Product Type and Application
3.8 Global Antiviral Drugs for Influenza Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Antiviral Drugs for Influenza Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Antiviral Drugs for Influenza Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Antiviral Drugs for Influenza Market by Type
4.1 Antiviral Drugs for Influenza Type Introduction
4.1.1 Neuraminidase Inhibitors
4.1.2 Polymerase Inhibitors
4.2 Global Antiviral Drugs for Influenza Sales Volume by Type
4.2.1 Global Antiviral Drugs for Influenza Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Antiviral Drugs for Influenza Sales Volume by Type (2020-2031)
4.2.3 Global Antiviral Drugs for Influenza Sales Volume Share by Type (2020-2031)
4.3 Global Antiviral Drugs for Influenza Sales Value by Type
4.3.1 Global Antiviral Drugs for Influenza Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Antiviral Drugs for Influenza Sales Value by Type (2020-2031)
4.3.3 Global Antiviral Drugs for Influenza Sales Value Share by Type (2020-2031)
5 Antiviral Drugs for Influenza Market by Application
5.1 Antiviral Drugs for Influenza Application Introduction
5.1.1 Over-the-counter (OTC)
5.1.2 Prescription (Rx)
5.2 Global Antiviral Drugs for Influenza Sales Volume by Application
5.2.1 Global Antiviral Drugs for Influenza Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Antiviral Drugs for Influenza Sales Volume by Application (2020-2031)
5.2.3 Global Antiviral Drugs for Influenza Sales Volume Share by Application (2020-2031)
5.3 Global Antiviral Drugs for Influenza Sales Value by Application
5.3.1 Global Antiviral Drugs for Influenza Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Antiviral Drugs for Influenza Sales Value by Application (2020-2031)
5.3.3 Global Antiviral Drugs for Influenza Sales Value Share by Application (2020-2031)
6 Antiviral Drugs for Influenza Regional Sales and Value Analysis
6.1 Global Antiviral Drugs for Influenza Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Antiviral Drugs for Influenza Sales by Region (2020-2031)
6.2.1 Global Antiviral Drugs for Influenza Sales by Region: 2020-2025
6.2.2 Global Antiviral Drugs for Influenza Sales by Region (2026-2031)
6.3 Global Antiviral Drugs for Influenza Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Antiviral Drugs for Influenza Sales Value by Region (2020-2031)
6.4.1 Global Antiviral Drugs for Influenza Sales Value by Region: 2020-2025
6.4.2 Global Antiviral Drugs for Influenza Sales Value by Region (2026-2031)
6.5 Global Antiviral Drugs for Influenza Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Antiviral Drugs for Influenza Sales Value (2020-2031)
6.6.2 North America Antiviral Drugs for Influenza Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Antiviral Drugs for Influenza Sales Value (2020-2031)
6.7.2 Europe Antiviral Drugs for Influenza Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Antiviral Drugs for Influenza Sales Value (2020-2031)
6.8.2 Asia-Pacific Antiviral Drugs for Influenza Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Antiviral Drugs for Influenza Sales Value (2020-2031)
6.9.2 South America Antiviral Drugs for Influenza Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Antiviral Drugs for Influenza Sales Value (2020-2031)
6.10.2 Middle East & Africa Antiviral Drugs for Influenza Sales Value Share by Country, 2024 VS 2031
7 Antiviral Drugs for Influenza Country-level Sales and Value Analysis
7.1 Global Antiviral Drugs for Influenza Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Antiviral Drugs for Influenza Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Antiviral Drugs for Influenza Sales by Country (2020-2031)
7.3.1 Global Antiviral Drugs for Influenza Sales by Country (2020-2025)
7.3.2 Global Antiviral Drugs for Influenza Sales by Country (2026-2031)
7.4 Global Antiviral Drugs for Influenza Sales Value by Country (2020-2031)
7.4.1 Global Antiviral Drugs for Influenza Sales Value by Country (2020-2025)
7.4.2 Global Antiviral Drugs for Influenza Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.5.2 USA Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.6.2 Canada Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.8.2 Germany Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.9.2 France Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.9.3 France Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.11.2 Italy Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.12.2 Spain Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.13.2 Russia Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.16.2 China Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.16.3 China Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.17.2 Japan Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.19.2 India Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.19.3 India Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.20.2 Australia Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.24.2 Chile Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.26.2 Peru Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.28.2 Israel Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.29.2 UAE Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.31.2 Iran Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Antiviral Drugs for Influenza Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Antiviral Drugs for Influenza Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Antiviral Drugs for Influenza Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 AdvaCare Pharma
8.1.1 AdvaCare Pharma Comapny Information
8.1.2 AdvaCare Pharma Business Overview
8.1.3 AdvaCare Pharma Antiviral Drugs for Influenza Sales, Value and Gross Margin (2020-2025)
8.1.4 AdvaCare Pharma Antiviral Drugs for Influenza Product Portfolio
8.1.5 AdvaCare Pharma Recent Developments
8.2 Avexima
8.2.1 Avexima Comapny Information
8.2.2 Avexima Business Overview
8.2.3 Avexima Antiviral Drugs for Influenza Sales, Value and Gross Margin (2020-2025)
8.2.4 Avexima Antiviral Drugs for Influenza Product Portfolio
8.2.5 Avexima Recent Developments
8.3 BioCryst Pharmaceuticals
8.3.1 BioCryst Pharmaceuticals Comapny Information
8.3.2 BioCryst Pharmaceuticals Business Overview
8.3.3 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Sales, Value and Gross Margin (2020-2025)
8.3.4 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
8.3.5 BioCryst Pharmaceuticals Recent Developments
8.4 Daiichi Sankyo
8.4.1 Daiichi Sankyo Comapny Information
8.4.2 Daiichi Sankyo Business Overview
8.4.3 Daiichi Sankyo Antiviral Drugs for Influenza Sales, Value and Gross Margin (2020-2025)
8.4.4 Daiichi Sankyo Antiviral Drugs for Influenza Product Portfolio
8.4.5 Daiichi Sankyo Recent Developments
8.5 Morningside Pharmaceuticals
8.5.1 Morningside Pharmaceuticals Comapny Information
8.5.2 Morningside Pharmaceuticals Business Overview
8.5.3 Morningside Pharmaceuticals Antiviral Drugs for Influenza Sales, Value and Gross Margin (2020-2025)
8.5.4 Morningside Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
8.5.5 Morningside Pharmaceuticals Recent Developments
8.6 Shionogi
8.6.1 Shionogi Comapny Information
8.6.2 Shionogi Business Overview
8.6.3 Shionogi Antiviral Drugs for Influenza Sales, Value and Gross Margin (2020-2025)
8.6.4 Shionogi Antiviral Drugs for Influenza Product Portfolio
8.6.5 Shionogi Recent Developments
8.7 Wockhardt
8.7.1 Wockhardt Comapny Information
8.7.2 Wockhardt Business Overview
8.7.3 Wockhardt Antiviral Drugs for Influenza Sales, Value and Gross Margin (2020-2025)
8.7.4 Wockhardt Antiviral Drugs for Influenza Product Portfolio
8.7.5 Wockhardt Recent Developments
8.8 GlaxoSmithKline
8.8.1 GlaxoSmithKline Comapny Information
8.8.2 GlaxoSmithKline Business Overview
8.8.3 GlaxoSmithKline Antiviral Drugs for Influenza Sales, Value and Gross Margin (2020-2025)
8.8.4 GlaxoSmithKline Antiviral Drugs for Influenza Product Portfolio
8.8.5 GlaxoSmithKline Recent Developments
8.9 Roche
8.9.1 Roche Comapny Information
8.9.2 Roche Business Overview
8.9.3 Roche Antiviral Drugs for Influenza Sales, Value and Gross Margin (2020-2025)
8.9.4 Roche Antiviral Drugs for Influenza Product Portfolio
8.9.5 Roche Recent Developments
8.10 Teva Pharmaceuticals
8.10.1 Teva Pharmaceuticals Comapny Information
8.10.2 Teva Pharmaceuticals Business Overview
8.10.3 Teva Pharmaceuticals Antiviral Drugs for Influenza Sales, Value and Gross Margin (2020-2025)
8.10.4 Teva Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
8.10.5 Teva Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Antiviral Drugs for Influenza Value Chain Analysis
9.1.1 Antiviral Drugs for Influenza Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Antiviral Drugs for Influenza Sales Mode & Process
9.2 Antiviral Drugs for Influenza Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Antiviral Drugs for Influenza Distributors
9.2.3 Antiviral Drugs for Influenza Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.